Neurology published a special article to evaluate the use of pharmacologic treatments for spasticity in children with cerebral palsy. The multidisciplinary panel reviewed articles from from 1966 through 2008. The panel concluded that Botulinum toxin type A was found to be generally safe although the FDA is currently investigated the use of the drug in children. Botox was found to be effective in reducing spasticity in the upper and lower extremities but there is inconsistent evidence regarding improvement in function. The panel concluded that that diazepam is effective in treating generalized spasticity along with tizanidine. There was inconclusive evidence on diazepam and tizanidine's effects on function. Regarding the use of phenol, alchohol, botox type B, dantrolene, oral baclofen, or continuous intrathecal baclofen, there was insufficient evidence to support or discredit their use.
Reference: Delgado, M. R., Hirtz, D., Aisen, M., Ashwal, S., Fehlings, D. L., McLaughlin, J., Morrison, L. A., Shrader, M. W., Tilton, A., Vargus-Adams, J.Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology SocietyNeurology 2010 74: 336-343